Series A · Healthtech

Robeauté raises $28 million Series A for brain microrobots

Plural, Cherry Ventures and Kindred Ventures co-led the equity round to advance neurosurgical microrobots and prepare US clinical development.

Robeauté raised $28 million in a Series A equity round co-led by Plural, Cherry Ventures and Kindred Ventures. LocalGlobe, Think.Health and existing backer APEX Ventures also participated, alongside strategic investor Brainlab.

The Paris company plans to use the financing to develop its neurosurgical microrobots, prepare human trials and establish US operations as it pursues regulatory approval. Advanced biopsy is its first application: a small robotic carrier is designed to move through curved routes in brain tissue and reach multiple sampling sites.

From laboratory development to clinical studies

Robeauté’s year-end review subsequently confirmed the Series A and described continued preclinical validation. The company is developing a broader platform around the carrier, interchangeable procedure extensions, a launching and tracking system, and control software. Clinical studies and regulatory authorization remain essential steps before commercial use.

Use of funds

Develop neurosurgical microrobotics

Prepare human clinical trials

Establish US operations and pursue regulatory approval

Funding history

Series A · This round$28M

Sources

  1. Robeauté raises $28 millionrobeaute.com
  2. 2025 Wrap: Letter from Co-foundersrobeaute.com · Dec 31, 2025
  3. Why we invested in Robeautépluralplatform.com · Jan 13, 2025
  4. Robeauté original financing announcementfortune.com · Jan 13, 2025